Literature DB >> 33294429

Tamoxifen induces stem-like phenotypes and multidrug resistance by altering epigenetic regulators in ERα+ breast cancer cells.

Aparna Kalyanaraman1, Dhanavathy Gnanasampanthapandian1, Prasad Shanmughan1, Puneet Kishore1, Satish Ramalingam2, Rathnaswami Arunachalam3, Selvaraj Jayaraman4, Ilango Kaliappan5, Ganesh Munuswamy-Ramanujam6, Ilangovan Ramachandran7, Yuvaraj Sambandam7, Muralidharan Anbalagan8, Parthasarathy Chandrakesan9, Kanagaraj Palaniyandi1.   

Abstract

BACKGROUND: To understand the mechanism underlying tamoxifen-induced multidrug resistance (MDR) and stem-like phenotypes in breast cancer cells, we treated the MCF-7 cells with 4-hydroxy-tamoxifen (TAM) for 6 months continuously and established MCF-7 tamoxifen resistance (TR) phenotypes.
METHODS: In the present study, the following methods were used: cell viability assay, colony formation, cell cycle analysis, ALDEFLUOR assay, mammosphere formation assay, chromatin immunoprecipitation (ChIP) assay, PCR array, western blot analysis and quantitative reverse transcription polymerase chain reaction (QRT-PCR).
RESULTS: The expression of ERα was significantly higher in MCF7-TR cells when compared with parental MCF-7 cells. MCF7-TR cells exposed to TAM showed a significant increase in the proliferation and rate of colony formation. The number of cancer stem cells was higher in MCF7-TR cells as observed by the increase in the number of ALDH+ cells. Furthermore, the number of mammospheres formed from the FACS-sorted ALDH+ cells was higher in MCF7-TR cells. Using PCR array analysis, we were able to identify that the long-term exposure of TAM leads to alterations in the epigenetic and MDR stem cell marker genes. Furthermore, western blot analysis demonstrated elevated levels of Notch-1 expression in MCF-TR cells compared with MCF-7 cells. Chromatin immunoprecipitation (ChIP) assay revealed that Notch-1 enhanced the cyclin D1 expression significantly in these cells. In addition, we observed that MCF7-TR cells were resistant to doxorubicin but not the MCF-7 cells.
CONCLUSIONS: In the present study, we conclude that the treatment with tamoxifen induces multiple epigenetic alterations that lead to the development of MDR and stem-like phenotypes in breast cancers. Therefore, our study provides better insights to develop novel treatment regime to control the progression of breast cancer. 2020 Stem Cell Investigation. All rights reserved.

Entities:  

Keywords:  Notch-1; Tamoxifen resistance (TR); breast cancer stem cells; epigenetics; multidrug resistance (MDR)

Year:  2020        PMID: 33294429      PMCID: PMC7715663          DOI: 10.21037/sci-2020-020

Source DB:  PubMed          Journal:  Stem Cell Investig        ISSN: 2306-9759


  37 in total

1.  Human Breast Cancer Stem Cells Have Significantly Higher Rate of Clathrin-Independent and Caveolin-Independent Endocytosis than the Differentiated Breast Cancer Cells.

Authors:  Kanagaraj Palaniyandi; Barbara A Pockaj; Sandra J Gendler; Xiu-Bao Chang
Journal:  J Cancer Sci Ther       Date:  2012-07-26

2.  The analysis of estrogen receptor-α positive breast cancer stem-like cells unveils a high expression of the serpin proteinase inhibitor PI-9: Possible regulatory mechanisms.

Authors:  Marianna Lauricella; Daniela Carlisi; Michela Giuliano; Giuseppe Calvaruso; Cesare Cernigliaro; Renza Vento; Antonella D'Anneo
Journal:  Int J Oncol       Date:  2016-04-21       Impact factor: 5.650

3.  Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells.

Authors:  Hoo Kyun Choi; Jin Won Yang; Sang Hee Roh; Chang Yeob Han; Keon Wook Kang
Journal:  Endocr Relat Cancer       Date:  2007-06       Impact factor: 5.678

4.  JMJD3 suppresses stem cell-like characteristics in breast cancer cells by downregulation of Oct4 independently of its demethylase activity.

Authors:  Jing Xun; Dekun Wang; Long Shen; Junbo Gong; Ruifang Gao; Lingfang Du; Antao Chang; Xiangrong Song; Rong Xiang; Xiaoyue Tan
Journal:  Oncotarget       Date:  2017-03-28

5.  Polymorphisms of ESR1, UGT1A1, HCN1, MAP3K1 and CYP2B6 are associated with the prognosis of hormone receptor-positive early breast cancer.

Authors:  Sung-Hsin Kuo; Shi-Yi Yang; San-Lin You; Huang-Chun Lien; Ching-Hung Lin; Po-Han Lin; Chiun-Sheng Huang
Journal:  Oncotarget       Date:  2017-03-28

6.  Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors.

Authors:  Yanrong Su; Nathan R Hopfinger; Theresa D Nguyen; Thomas J Pogash; Julia Santucci-Pereira; Jose Russo
Journal:  J Exp Clin Cancer Res       Date:  2018-12-14

7.  Sulforaphane-induced metabolomic responses with epigenetic changes in estrogen receptor positive breast cancer cells.

Authors:  Shuyuan Cao; Li Wang; Zhan Zhang; Feng Chen; Qian Wu; Lei Li
Journal:  FEBS Open Bio       Date:  2018-11-14       Impact factor: 2.693

8.  Crosstalk between PKCα and Notch-4 in endocrine-resistant breast cancer cells.

Authors:  J Yun; A Pannuti; I Espinoza; H Zhu; C Hicks; X Zhu; M Caskey; P Rizzo; G D'Souza; K Backus; M F Denning; J Coon; M Sun; E H Bresnick; C Osipo; J Wu; P R Strack; D A Tonetti; L Miele
Journal:  Oncogenesis       Date:  2013-08-05       Impact factor: 7.485

9.  ABCB1 and ABCC2 and the risk of distant metastasis in Thai breast cancer patients treated with tamoxifen.

Authors:  Insee Sensorn; Chonlaphat Sukasem; Ekaphop Sirachainan; Montri Chamnanphon; Ekawat Pasomsub; Narumol Trachu; Porntip Supavilai; Darawan Pinthong; Sansanee Wongwaisayawan
Journal:  Onco Targets Ther       Date:  2016-04-12       Impact factor: 4.147

10.  CD44/CD24 and aldehyde dehydrogenase 1 in estrogen receptor-positive early breast cancer treated with tamoxifen: CD24 positivity is a poor prognosticator.

Authors:  Yong Wha Moon; Hee-Jung An; Ja Seung Koo; Gun Min Kim; Hyunju Han; Seho Park; Seung Il Kim; Hyung Seok Park; Sewha Kim; Seung Ki Kim; Seung Ah Lee; Sohyun Hwang; Gun Woo Son; Joohyuk Sohn
Journal:  Oncotarget       Date:  2017-12-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.